SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC filings, Ayabudge LLC, an entity controlled by Board member Brady W. Dougan, who is married to CEO and President Laura Niklason, disposed of 1.5 million shares over three days in November, netting approximately $6.6 million. The sales, which were treated as indirectly benefiting Dr. Niklason, came as Humacyte navi ...

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/humacyte-inc-laws ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Humacyte, Inc. regarding a class action lawsuit due to alleged misleading statements and failures to disclose critical information during a specified class period [1][2]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from May 10, 2024, to October 17, 2024 [2]. - Allegations include that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, which included issues with quality assurance and microbial testing [2]. - It is claimed that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies, posing a substantial risk to FDA approval of their acellular tissue engineered vessel for vascular trauma [2]. - The lawsuit asserts that the positive statements made by the company regarding its business and prospects were materially misleading and lacked a reasonable basis [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of January 17, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [4].

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=117013&from=3 CLASS PERIOD: May 10, 2024 to O ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Humacyte, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 17, 2025 [2][4]. Group 1: Allegations Against Humacyte - The complaint alleges that Humacyte and its executives made false or misleading statements and failed to disclose significant issues regarding their manufacturing practices and FDA approval process [4]. - Specific allegations include non-compliance with good manufacturing practices at the Durham, North Carolina facility, leading to delays in the FDA's review of the Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) [4]. - The complaint suggests that these issues posed a substantial risk to the FDA approval of ATEV for vascular trauma, rendering the company's positive statements materially misleading [4]. Group 2: Stock Price Impact - Following a press release on August 9, 2024, regarding the FDA's need for additional time to review the BLA, Humacyte's stock price fell by $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [5]. - On October 17, 2024, the FDA released a Form 483 detailing violations at Humacyte's facility, resulting in a further decline of $0.95, or 16.35%, with the stock closing at $4.86 per share on the same day [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 between May 10, 2024, and October 17, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for January 17, 2025 [2][7].

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=116392&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

Core Viewpoint - A class action securities lawsuit has been filed against Humacyte, Inc. due to alleged securities fraud affecting investors between May 10, 2024, and October 17, 2024 [1] Group 1: Allegations - The lawsuit claims that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, including quality assurance and microbial testing [2] - It is alleged that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies [2] - There is a substantial risk to the FDA approval of Humacyte's acellular tissue engineered vessel for vascular trauma as a result of these issues [2] - The defendants' positive statements regarding the company's business and prospects were misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 17, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]

NEW YORK, Dec. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=114728&from=4CLASS PERIOD: May 10, 2024 to October 17 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Humacyte, Inc. regarding a class action lawsuit due to alleged misleading statements and failures to disclose critical information during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 10, 2024, to October 17, 2024 [3]. - Allegations include that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, which included issues with quality assurance and microbial testing [3]. - It is claimed that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies, posing a substantial risk to FDA approval of their acellular tissue engineered vessel for vascular trauma [3]. - The lawsuit asserts that the defendants made materially misleading statements about the company's business, operations, and prospects, lacking a reasonable basis [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 17, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of Humacyte's stock [5].

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who purchased Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, alleging that the company misled investors regarding its manufacturing practices and the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel [1][2][3]. Group 1: Allegations and Impact - Humacyte is engaged in the development of Acellular Tissue Engineered Vessel (ATEV), a lab-grown blood vessel implant [2]. - On August 9, 2024, Humacyte announced that the FDA required additional time to review its BLA, leading to a stock price decline of $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [2]. - On October 17, 2024, the FDA issued a Form 483 revealing violations at Humacyte's Durham facility, including lack of microbial quality assurance and inadequate quality oversight, causing the stock price to drop by $0.95, or 16.35%, to close at $4.86 per share [2][3]. Group 2: Disclosure Failures - The complaint alleges that Humacyte failed to disclose that its Durham facility did not comply with good manufacturing practices, which included quality assurance and microbial testing [3]. - It is claimed that the company did not inform investors that the FDA's review of the BLA would be delayed due to the need for remediation of these deficiencies [3]. - The allegations suggest that there was a substantial risk to the FDA approval of ATEV for vascular trauma as a result of these undisclosed issues [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by January 17, 2025 [4]. - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [5].